据华尔街报道， 礼来 正在就以超过10亿美元收购生物技术公司 Ve n t y x Bios c i e n c e s (NAS D AQ:VTYX) 进行后期谈判，美股收盘后股价暴涨57%。 Clinical catalysts represent three potential paths to meaningful value creation in 2025: Late-stage Inflammatory Bowel Disease portfolio provides potential additional source of value: Internally Discovered Clinical-Stage Pipeline Addressing Autoimmune, Inflammatory and Neurodegenerative Diseases with High Unmet Need | 最高: 25.00 | 今开:7.90 | 成交量: 639.75万股 | 换手:8.97% | | --- | --- | --- | --- | | 最低: 7.08 | 昨收:7.8 ...